Drug intelligence / Profile preview

RuL2

Development stage: Preclinical
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules

Overview

RuL2 is a ruthenium complex synthesized with an α-amino acid, l-alanine, and 2,3-dihydroxybenzaldehyde derived Schiff base. It has demonstrated significant binding towards human serum albumin (HSA) and exhibits concentration-dependent cytotoxicity in human hepatocellular carcinoma (HepG2) cell lines. Its cytotoxic effects are mediated via protein binding and the generation of reactive oxygen species (ROS).

Beyond the preview

Go deeper on RuL2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RuL2.

Explore the full profile